Fate Therapeutics, Inc.
FATE
$1.06
-$0.07-6.20%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -32.37M | -32.25M | -34.07M | -37.62M | -52.15M |
| Total Depreciation and Amortization | 3.06M | 3.23M | 3.28M | 3.33M | 4.81M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.94M | 4.15M | 6.13M | 5.85M | 21.45M |
| Change in Net Operating Assets | 1.06M | 504.00K | 73.00K | -5.37M | -1.91M |
| Cash from Operations | -23.31M | -24.37M | -24.59M | -33.81M | -27.80M |
| Capital Expenditure | -1.19M | -2.20M | -1.36M | -1.20M | -98.00K |
| Sale of Property, Plant, and Equipment | 237.00K | 3.00K | 122.00K | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 28.59M | 23.47M | 20.83M | 43.87M | 22.91M |
| Cash from Investing | 27.63M | 21.27M | 19.59M | 42.67M | 22.82M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 1.69M | 2.48M | 1.33M | -- | 3.13M |
| Cash from Financing | 1.69M | 2.48M | 1.33M | -- | 3.13M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 6.01M | -627.00K | -3.67M | 8.86M | -1.85M |